1 |
ClinicalTrials.gov (NCT04677803) A Phase 2a Multiple Dose Basket Study of the Safety, Tolerability, and Pharmacologic Activity of BT200 in Patients With Hereditary Bleeding Disorders. U.S.National Institutes of Health.
|
2 |
Clinical pipeline report, company report or official report of Guardian Theapeutics
|
3 |
Clinical pipeline report, company report or official report of Vonvendi.
|
4 |
Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
|
5 |
6 Factor VIII Concentrates, Factor VIII/von Willebrand Factor Concentrates, Factor IX Concentrates, Activated Prothrombin Complex Concentrates. Transfus Med Hemother. 2009 December; 36(6): 409-418.
|
6 |
Clinical pipeline report, company report or official report of Ablynx
|
7 |
Short-Acting Anti-VWF (von Willebrand Factor) Aptamer Improves the Recovery, Survival, and Hemostatic Functions of Refrigerated Platelets. Arterioscler Thromb Vasc Biol. 2019 Oct;39(10):2028-2037.
|
8 |
A new oral antiplatelet agent with potent antithrombotic properties: comparison of DZ-697b with clopidogrel a randomised phase I study. Thromb Haemost. 2010 Jan;103(1):205-12.
|
9 |
Clinical pipeline report, company report or official report of Basking Biosciences
|
10 |
Novel approaches to the treatment of thrombosis. Trends Pharmacol Sci. 2002 Jan;23(1):25-32.
|
|
|
|
|
|
|